$0.84
2.4%
Price vs. AI Score (Last 150 days)
Data gathered: December 6
Data gathered: December 6
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | 8 0% |
|
| Sentiment | 79 5.3% |
|
| Webpage traffic | 17,000 6% |
|
| Employee Rating | 76 0% |
|
| Google Trends | 0% |
|
| Linkedin Employees | 418 N/A |
|
| Patents | 30 0% |
|
| 4chan Mentions | 0% | N/A |
| Facebook Engagement | 1 0% |
|
| Facebook followers | 876 0% |
|
| Stocktwits Mentions | 6 -25% |
|
| Stocktwits Subscribers | 7,941 -0.1% |
|
| Twitter Followers | 1,524 0% |
|
| News Mentions | 0% |
|
| Reddit Mentions | 0% |
|
| Business outlook | 64 0% |
|
In the news
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)December 3 - Finnhub |
|
 |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 1 - Yahoo |
 |
Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But RiskyNovember 29 - SeekingAlpha |
Karyopharm Therapeutics; Promising Potential With 3 Ongoing Phase 3 Studies But RiskyNovember 28 - Seeking Alpha |
|
|
Karyopharm to Participate at Upcoming Investor ConferencesNovember 8 - Yahoo |
|
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyNovember 5 - Yahoo |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $0.84 |
| Target Price | Sign up |
| Market Cap | $100M |
| Dividend Yield | 0 |
| Industry | Biotechnology |
Similar companies
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 30M | 31M | -870,000 | -35M | -28M |
| Q2 '23 | 32M | 34M | -2.7M | -33M | -27M |
| Q1 '23 | 33M | 36M | -3M | -34M | -28M |
| Q4 '22 | 28M | 35M | -7M | -39M | -33M |
| Q3 '22 | 30M | 35M | -4.6M | -36M | -30M |
Insider Transactions
| Paulson Richard A. filed to sell 787,579 shares at $0.8. December 5 '23 |
| Paulson Richard A. filed to sell 791,201 shares at $0.9. November 7 '23 |
| Paulson Richard A. filed to sell 794,807 shares at $1.3. October 5 '23 |
| Paulson Richard A. filed to sell 798,396 shares at $1.3. September 6 '23 |
| Cheng Sohanya Roshan filed to sell 204,086 shares at $1.3. September 5 '23 |
Read more about Karyopharm Therapeutics and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google trends, linkedin employees, patents, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, reddit mentions, business outlook.